David T Wu

US Patent:

8364815, Jan 29, 2013

Filed:

Oct 3, 2005

Appl. No.:

11/243068

Inventors:

Daniel Edwin Burman - Flower Mound TX, US
Kartik Subbanna - Fremont CA, US
Steven McCanne - Berkeley CA, US
David Tze-Si Wu - Fremont CA, US
Mark Stuart Day - Milton MA, US

Assignee:

Riverbed Technology, Inc. - San Francisco CA

International Classification:

G06F 15/173
G06F 15/16

US Classification:

709225, 709218

Abstract:

A system of network proxies distributes data to multiple servers. Each network proxy is associated with a server. A network proxy intercepts a client request for data. If the network proxy determines that the request can be served using a copy of data stored on the local server, rather than the data stored on a remote server, it diverts the request to the local server. If the network proxy determines that the request cannot be served using a data from the local server, the network proxy diverts the request to a remote server storing the primary copy of the data. A server map specifies the locations of the primary copies of data. When a primary copy of data is updated on one of the servers, the associated network proxy propagates the updated data to the other servers. The servers can provide data from files, e-mail services, databases, or multimedia services.

US Patent:

20090203141, Aug 13, 2009

Filed:

Jan 8, 2009

Appl. No.:

12/318806

Inventors:

David TS Wu - Arcadia CA, US

International Classification:

C12N 15/86
C12N 15/74

US Classification:

435456, 435455, 4353201

Abstract:

The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On/Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA)/shRNA agent under the control of doxycyclin (Dox) in human somatic/cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.

US Patent:

20100329648, Dec 30, 2010

Filed:

Jun 24, 2010

Appl. No.:

12/823087

Inventors:

Arbel D. TADMOR - Pasadena CA, US
David Wu - Los Angeles CA, US

International Classification:

H04N 5/783
H04N 7/18

US Classification:

386343, 348143, 386E05003

Abstract:

A system and a method of ensuring correct execution of a laboratory protocol or procedure are provided. An embodiment of the disclosure records videos of a bench area with a monitoring device, processes and stores the recorded video, and allows users to review the video. By reviewing the video of the lab procedure while conducting the laboratory protocol or procedure or shortly thereafter, users can resolve doubts and problems about particular steps of the lab procedure and conduct the procedure correctly.

US Patent:

62437119, Jun 5, 2001

Filed:

Mar 6, 1998

Appl. No.:

9/036316

Inventors:

David Tze-Si Wu - Hacienda Heights CA
Jeffrey G. Ichnowski - Palo Alto CA

Assignee:

eALITY, Inc. - Foster City CA

International Classification:

G06F 1730

US Classification:

707104

Abstract:

A system for providing a form description language for a networked database program is disclosed. In one embodiment of the present invention, a database form is described using a plurality of components. Each component describes a particular item or entity within the database form. The size and placement of each of the various items in a database form is specified relative to the other items. The programming objects defining the structure of the database are created and stored separately from the data objects defining the data entered into the database by a user. A description language interpreter transmitted in conjunction with the database form allows display of the database form by executing the self-contained interpreter.

US Patent:

20200165607, May 28, 2020

Filed:

Aug 5, 2019

Appl. No.:

16/532353

Inventors:

Donald C. Chang - Cerritos CA, US
David TS Wu - Arcadia CA, US
Hsuan-Hsuan Lu - Taipei City, TW

International Classification:

C12N 15/113
C12N 15/11

Abstract:

This invention generally relates to a composition and method of using mam-made small RNAs, such as small interfering RNAs (siRNA), microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic tumors, such as brain tumors and teratocarcinomas that contain a variety of tumorous and cancerous cells derived from all three germ layers of tissues, including ectoderm, mesoderm and endoderm. More specifically, the present invention relates to the use of miR-302-like siRNA (siR-302) and/or miR-302 precursors (pre-miR-302) for developing novel medicines and therapies against a variety of human cancers, in particular lung cancers.

US Patent:

20190325131, Oct 24, 2019

Filed:

Apr 24, 2018

Appl. No.:

15/961505

Inventors:

- Round Rock TX, US
James D. Testerman - McKinney TX, US
Ricardo A. Ruiz - The Colony TX, US
Jonathan N. Yanez - Allen TX, US
Luis A. Valencia Reyes - Garland TX, US
David Wu - Allen TX, US

Assignee:

Dell Products, LP - Round Rock TX

International Classification:

G06F 21/54
G06F 21/60
G06F 9/445
H04N 1/32
G06T 1/00

Abstract:

An information handling system operating a forced data leakage prevention system may comprise a processor executing code instructions of the forced data leakage prevention system to identify a third party application and an associated first dynamic link library address, identify a control policy associated with the third party application and the identified user, wherein the control policy includes a subset of code instructions associated with a secure data set, identify a call to execute code instructions stored at the first dynamic link library address, move the code instructions stored at the first dynamic link library into a second library prior to execution, inject the subset of code instructions into the code instructions stored in the second library according to the control policy, and move the code instructions stored in the second library including the injected subset of code instructions into the first dynamic link library for execution by the processor.

US Patent:

20170175118, Jun 22, 2017

Filed:

Feb 24, 2017

Appl. No.:

15/442557

Inventors:

Donald C. Chang - Cerritos CA, US
David TS Wu - Arcadia CA, US
Hsuan-Hsuan Lu - Taipei City, TW

International Classification:

C12N 15/113

Abstract:

This invention generally relates to a composition and method of using mam-made small RNAs, such as small interfering RNAs (siRNA), microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic tumors, such as brain tumors and teratocarcinomas that contain a variety of tumorous and cancerous cells derived from all three germ layers of tissues, including ectoderm, mesoderm and endoderm. More specifically, the present invention relates to the use of miR-302-like siRNA (siR-302) and/or miR-302 precursors (pre-miR-302) for developing novel medicines and therapies against a variety of human cancers, in particular lung cancers.

US Patent:

20160289682, Oct 6, 2016

Filed:

May 27, 2016

Appl. No.:

15/167219

Inventors:

David TS WU - Arcadia CA, US

International Classification:

C12N 15/113

Abstract:

This invention generally relates to a design and method for developing novel anti-tumor and/or anti-cancer drugs, vaccines and therapies, using microRNA and/or its shRNA homologues/mimics/derivatives. More specifically, the present invention relates to an use of a prokaryote-produced miRNA precursor (pro-miRNA) composition capable of being delivered into human cells and processed by the cells into mature miRNA effectors to elicit specific silencing effects on mir-302-targeted genes, subsequently leading to a beneficial result of tumor suppression and cancer therapy. The prokaryotic cells do not naturally express or process eukaryotic miRNA precursors (pre-miRNA); meanwhile, the present invention also teaches an inducible method for expressing pre-miRNAs, particularly mir-302 precursors by using the prokaryotic transcription system. Since mir-302 is a known tumor suppressor in human, this novel finding advances the design and method for developing new anti-cancer drugs, vaccines and/or therapies directed against multiple kinds of human tumors and cancers.

Author:

David Wu

ISBN #:

0195058895

Author:

David Y. Wu

ISBN #:

0127016309